Bayer AG: EPS $0.11 vs $0.13 expected; revenue $11.3B vs $11.2B
Key Facts
Q3 FY2026 results
| Metric | Actual | Estimate | Surprise | Year ago |
|---|---|---|---|---|
| EPS (USD) | 0.11 | 0.13 | −15.4% | 0.17 |
| Revenue (USD bn) | 11.26 | 11.21 | +0.4% | 13.22 |
Recent reports: actual vs estimate
| Reported | Period | EPS (USD) | Estimate | Surprise | Revenue (USD bn) | Estimate | Surprise |
|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | Q3 FY2026 | 0.11 | 0.1300 | −15.4% | 11.26 | 11.21 | +0.4% |
| Aug 4, 2026 | Q2 FY2026 | 0.29 | 0.2300 | +26.1% | 12.53 | 12.31 | +1.8% |
| May 12, 2026 | Q1 FY2026 | 0.79 | 0.6400 | +23.4% | 15.73 | 15.77 | −0.3% |
| Mar 4, 2026 | Q4 FY2025 | 0.18 | 0.1800 | 0.0% | 13.31 | 13.11 | +1.6% |
| Nov 12, 2025 | Q3 FY2025 | 0.17 | 0.1300 | +30.8% | 13.22 | 13.09 | +1.0% |
| Aug 6, 2025 | Q2 FY2025 | 0.35 | 0.2500 | +40.0% | 12.64 | 11.33 | +11.6% |
| Mar 5, 2025 | Q4 FY2024 | 0.28 | 0.2592 | +8.0% | 12.63 | 11.93 | +5.9% |
| Nov 12, 2024 | Q3 FY2024 | 0.07 | 0.1700 | −58.8% | 10.93 | 12.16 | −10.1% |
Source: Figures from the EL7 database. Estimates are the analyst consensus carried by our data vendor (FMP), not official figures.
Bayer AG results: EPS $0.11 vs $0.13 expected; revenue $11.3B vs $11.2B. The results cover the company's Q3 FY2026. EPS came in below analysts' estimate by 15.4%; revenue above the estimate by 0.4%.
Revenue was down 14.9% from $13.2 billion a year earlier (Q3 FY2025). EPS was down 35.3% from $0.17 a year earlier. On its record, EPS topped analysts' estimates in 5 of 7 earlier comparable reports.
What the results mean
Bayer AG combines prescription pharmaceuticals, consumer health products and crop science. Understanding its results therefore requires attention to the business mix: pharmaceuticals depend on treatment needs and product development, while agriculture serves farmers' needs for seeds and crop protection.
Interpreting profitability requires examining business contributions and research, development and marketing costs. Bayer AG's operations span specialized treatments, self-care products and agricultural solutions, so the direction of sales alone cannot explain business performance.
What to watch on the earnings call: The earnings call merits attention to management's discussion of demand across pharmaceuticals, consumer health and crop science, and how product mix and research and commercial spending affect margins. Details on treatment development and the role of research partnerships in supporting the product portfolio would also be useful.
For the full analysis of Bayer AG stock — valuation, scores and financial statements — see the stock page linked with this story.